We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Egetis Therapeutics AB (EGTX) NPV

Sell:5.37 SEK Buy:5.43 SEK Change: 0.03 SEK (0.56%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.37 SEK
Buy:5.43 SEK
Change: 0.03 SEK (0.56%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.37 SEK
Buy:5.43 SEK
Change: 0.03 SEK (0.56%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Contact details

Address:
Klara Norra Kyrkogata 26
STOCKHOLM
111 22
Sweden
Telephone:
+46 (8) 6797210
Website:
https://www.egetis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EGTX
ISIN:
SE0003815604
Market cap:
1.94 billion SEK
Shares in issue:
292.57 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Nicklas Westerholm
    Chief Executive Officer
  • Yilmaz Mahshid
    Chief Financial Officer
  • Anny Bedard
    President of Egetis North America
  • Katayoun Welin-Berger
    Vice President - Technical Operations
  • Karl Hard
    Vice President, Head - Investor Relations and Communications
  • Henrik Krook
    Vice President - Commercial Operations
  • Christian Sonesson
    Vice President - Product Strategy and Development
  • Nils Hallen
    Human Resources Manager
  • Kristina Nygren
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.